Download PDF
Journal of Pediatric Biochemistry 2016; 06(01): 019-024
DOI: 10.1055/s-0036-1582250
Review Article
Georg Thieme Verlag KG Stuttgart · New York

Neurological Involvement in Tetrahydrobiopterin Deficiency

Italia Mascaro
1   Department of Medical and Surgical Sciences, Pediatric Unit, Department of Pediatrics, University “Magna Graecia,” Catanzaro, Italy
,
Ferdinando Ceravolo
1   Department of Medical and Surgical Sciences, Pediatric Unit, Department of Pediatrics, University “Magna Graecia,” Catanzaro, Italy
,
Stefania Ferraro
1   Department of Medical and Surgical Sciences, Pediatric Unit, Department of Pediatrics, University “Magna Graecia,” Catanzaro, Italy
,
Daniela Procopio
1   Department of Medical and Surgical Sciences, Pediatric Unit, Department of Pediatrics, University “Magna Graecia,” Catanzaro, Italy
,
Francesca Falvo
1   Department of Medical and Surgical Sciences, Pediatric Unit, Department of Pediatrics, University “Magna Graecia,” Catanzaro, Italy
,
Michele Grisolia
1   Department of Medical and Surgical Sciences, Pediatric Unit, Department of Pediatrics, University “Magna Graecia,” Catanzaro, Italy
,
Giuseppina Leone
1   Department of Medical and Surgical Sciences, Pediatric Unit, Department of Pediatrics, University “Magna Graecia,” Catanzaro, Italy
,
Vincenzo Salpietro
2   Department of Pediatrics, University of Messina, Messina, Italy
3   Institute of Neurogenetics, National Hospital for Neurology and Neurosurgery, University College London Hospitals, London, United Kingdom
,
Agata Polizzi
4   National Centre for Rare Diseases, Istituto Superiore di Sanità, Rome, Italy
,
Martino Ruggieri
5   Department of Clinical and Experimental Medicine, Section of Pediatrics and Child Neuropsychiatry, University of Catania, Catania, Italy
,
Daniela Concolino
1   Department of Medical and Surgical Sciences, Pediatric Unit, Department of Pediatrics, University “Magna Graecia,” Catanzaro, Italy
› Author Affiliations
Further Information

Publication History

02 December 2015

15 January 2016

Publication Date:
26 April 2016 (online)

    Permissions and Reprints

Abstract

Tetrahydrobiopterin (BH4) is a natural and essential cofactor for the enzymatic hydroxylation of phenylalanine (Phe) and tyrosine (Tyr), and for two tryptophan hydroxylases, three nitric oxide synthases, and glyceryl-ether monooxygenase. Five separate genetic conditions affecting BH4 synthesis or recycling have been identified so far, including deficiency in (1) 6-pyruvoyltetrahydropterin synthase; (2) dihydropteridine reductase; (3) GTP cyclohydrolase I; (4) sepiapterin reductase; and (5) pterin-4α-carbinolamine dehydratase. These disorders cause hyperphenylalaninemia and impaired synthesis of serotonin and dopamine since tyrosine hydroxylase and neuronal tryptophan hydroxylase require BH4 and serotonin/dopamine products (5-hydroxytryptophan and L-dopa). All these five genetic conditions can be identified by newborn screening procedures due to elevated blood levels of Phe (with the sole exception of sepiapterin reductase deficiency). BH4 loading tests and measurement of neurotransmitter metabolites, pterins, and folates in cerebrospinal fluid can add further important information on disease severity. Untreated patients develop a complex neurological phenotype, which includes Parkinson-like features, brain degeneration, and early death. The gold standard treatment of severe disorders of BH4 metabolism is based on replacement therapy with BH4, 5-hydroxytryptophan, L-dopa, and carbidopa, with the addition, in certain cases, of folinic acid supplements and pramipexole. Dopamine agonists can improve L-dopa therapy, making treatment easier, relieving symptoms, stabilizing clinical course, and possibly ameliorating long-term outcomes. The outcome of patients with disorders of biopterin synthesis can be favorable, with either normal or near-normal cognition, and with some residual neurological symptoms usually manifesting diurnal variation, that is, worst when patients become tired or when the dosage or interval for medications is inadequate.

Keywords

tetrahydrobiopterin - hyperphenylalaninemia - dihydropteridine reductase - GTP cyclohydrolase I - homovanillic acid - pterin-4′-carbinolamine dehydratase - phenylalanine - 6-pyruvoyltetrahydropterin synthase - sepiapterin reductase
 

  • References

  • 1 Blau N, van Spronsen FJ, Levy HL. Phenylketonuria. Lancet 2010; 376 (9750) 1417-1427
    CrossrefPubMedGoogle Scholar
  • 2 Blau N, Hennermann JB, Langenbeck U, Lichter-Konecki U. Diagnosis, classification, and genetics of phenylketonuria and tetrahydrobiopterin (BH4) deficiencies. Mol Genet Metab 2011; 104 (Suppl): S2-S9
    CrossrefPubMedGoogle Scholar
  • 3 Longo N. Disorders of biopterin metabolism. J Inherit Metab Dis 2009; 32 (3) 333-342
    CrossrefPubMedGoogle Scholar
  • 4 Blau B, Thöny R, Cotton GH, Hyland K. Disorders of tetrahydrobiopterin and related biogenic amines. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Vogelstein B, eds. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill; 2001: 1725-1776
    Google Scholar
  • 5 Dhondt JL. Laboratory diagnosis of phenylketonuria. In: Blau N, ed. PKU and BH4: Advances in Phenylketonuria and Tetrahydrobiopterin. Heilbronn: SPS Verlagsgesellschaft; 2006: 161-179
    Google Scholar
  • 6 Porta F, Ponzone A, Spada M. Short prolactin profile for monitoring treatment in BH4 deficiency. Eur J Paediatr Neurol 2015; 19 (3) 360-363
    CrossrefPubMedGoogle Scholar
  • 7 Niederwieser A, Blau N, Wang M, Joller P, Atarés M, Cardesa-Garcia J. GTP cyclohydrolase I deficiency, a new enzyme defect causing hyperphenylalaninemia with neopterin, biopterin, dopamine, and serotonin deficiencies and muscular hypotonia. Eur J Pediatr 1984; 141 (4) 208-214
    CrossrefPubMedGoogle Scholar
  • 8 Maita N, Okada K, Hatakeyama K, Hakoshima T. Crystal structure of the stimulatory complex of GTP cyclohydrolase I and its feedback regulatory protein GFRP. Proc Natl Acad Sci U S A 2002; 99 (3) 1212-1217
    CrossrefPubMedGoogle Scholar
  • 9 Ponzone A, Spada M, Ferraris S, Dianzani I, de Sanctis L. Dihydropteridine reductase deficiency in man: from biology to treatment. Med Res Rev 2004; 24 (2) 127-150
    CrossrefPubMedGoogle Scholar
  • 10 Jäggi L, Zurflüh MR, Schuler A , et al. Outcome and long-term follow-up of 36 patients with tetrahydrobiopterin deficiency. Mol Genet Metab 2008; 93 (3) 295-305
    CrossrefPubMedGoogle Scholar
  • 11 Leuzzi V, Carducci CA, Carducci CL , et al. Phenotypic variability, neurological outcome and genetics background of 6-pyruvoyl-tetrahydropterin synthase deficiency. Clin Genet 2010; 77 (3) 249-257
    CrossrefPubMedGoogle Scholar
  • 12 Pavone P, Spalice A, Polizzi A, Parisi P, Ruggieri M. Ohtahara syndrome with emphasis on recent genetic discovery. Brain Dev 2012; 34 (6) 459-468
    CrossrefPubMedGoogle Scholar
  • 13 Pavone P, Striano P, Falsaperla R, Pavone L, Ruggieri M. Infantile spasms syndrome, West syndrome and related phenotypes: what we know in 2013. Brain Dev 2014; 36 (9) 739-751
    CrossrefPubMedGoogle Scholar
  • 14 Van der Knaap M, Valk J. Magnetic Resonance of Myelination and Myelin Disorders. 3rd ed. Berlin: Springer-Verlag; 2005
    CrossrefGoogle Scholar
  • 15 Patay Z. Metabolic disorders. In: Tortori-Donati P, ed. Pediatric Neuroradiology. Brain. . Berlin: Springer-Verlag; 2005: 543-722
    CrossrefGoogle Scholar
  • 16 Barkovich AJ. Pediatric Neuroradiology. 5th ed. Baltimore, MD: Lippincott Williams & Wilkins; 2012
    Google Scholar
  • 17 Porta F, Mussa A, Concolino D, Spada M, Ponzone A. Dopamine agonists in dihydropteridine reductase deficiency. Mol Genet Metab 2012; 105 (4) 582-584
    CrossrefPubMedGoogle Scholar
  • 18 Neville BG, Parascandalo R, Farrugia R, Felice A. Sepiapterin reductase deficiency: a congenital dopa-responsive motor and cognitive disorder. Brain 2005; 128 (Pt 10) 2291-2296
    CrossrefPubMedGoogle Scholar
  • 19 Abeling NG, Duran M, Bakker HD , et al. Sepiapterin reductase deficiency an autosomal recessive DOPA-responsive dystonia. Mol Genet Metab 2006; 89 (1–2) 116-120
    CrossrefPubMedGoogle Scholar
  • 20 Opladen T, Abu Seda B, Rassi A, Thöny B, Hoffmann GF, Blau N. Diagnosis of tetrahydrobiopterin deficiency using filter paper blood spots: further development of the method and 5 years experience. J Inherit Metab Dis 2011; 34 (3) 819-826
    CrossrefPubMedGoogle Scholar
  • 21 Hyland K, Surtees RA, Heales SJ, Bowron A, Howells DW, Smith I. Cerebrospinal fluid concentrations of pterins and metabolites of serotonin and dopamine in a pediatric reference population. Pediatr Res 1993; 34 (1) 10-14
    CrossrefPubMedGoogle Scholar
  • 22 Zorzi G, Thöny B, Blau N. Reduced nitric oxide metabolites in CSF of patients with tetrahydrobiopterin deficiency. J Neurochem 2002; 80 (2) 362-364
    CrossrefPubMedGoogle Scholar
  • 23 Hyland K. Inherited disorders affecting dopamine and serotonin: critical neurotransmitters derived from aromatic amino acids. J Nutr 2007; 137 (6) (Suppl. 01) 1568S-1572S , discussion 1573S–1575S
    PubMedGoogle Scholar
  • 24 Hyland K. Clinical utility of monoamine neurotransmitter metabolite analysis in cerebrospinal fluid. Clin Chem 2008; 54 (4) 633-641
    CrossrefPubMedGoogle Scholar
  • 25 Curtius HC, Niederwieser A, Viscontini M , et al. Atypical phenylketonuria due to tetrahydrobiopterin deficiency. Diagnosis and treatment with tetrahydrobiopterin, dihydrobiopterin and sepiapterin. Clin Chim Acta 1979; 93 (2) 251-262
    CrossrefPubMedGoogle Scholar
  • 26 Ponzone A, Guardamagna O, Dianzani I , et al. Catalytic activity of tetrahydrobiopterin in dihydropteridine reductase deficiency and indications for treatment. Pediatr Res 1993; 33 (2) 125-128
    CrossrefPubMedGoogle Scholar
  • 27 Bonafé L, Thöny B, Penzien JM, Czarnecki B, Blau N. Mutations in the sepiapterin reductase gene cause a novel tetrahydrobiopterin-dependent monoamine-neurotransmitter deficiency without hyperphenylalaninemia. Am J Hum Genet 2001; 69 (2) 269-277
    CrossrefPubMedGoogle Scholar
  • 28 Bartholomé K, Byrd DJ. Letter: L-dopa and 5-hydroxytryptophan therapy in phenylketonuria with normal phenylalanine-hydroxylase activity. Lancet 1975; 2 (7943) 1042-1043
    PubMedGoogle Scholar
  • 29 Schuler A, Blau N, Ponzone A. Monoamine oxidase inhibitors in tetrahydrobiopterin deficiency. Eur J Pediatr 1995; 154 (12) 997
    CrossrefPubMedGoogle Scholar
  • 30 Ponzone A, Baglieri S, Battistoni G, Martini A, Spada M. COMT inhibitors in the treatment of tetrahydrobiopterin deficiency. Pteridines 2001; 12: 70
    PubMedGoogle Scholar
  • 31 Tanaka Y, Matsuo N, Tsuzaki S, Araki K, Tsuchiya Y, Niederwieser A. On-off phenomenon in a child with tetrahydrobiopterin deficiency due to 6-pyruvoyl tetrahydropterin synthase deficiency (BH4 deficiency). Eur J Pediatr 1989; 148 (5) 450-452
    CrossrefPubMedGoogle Scholar
  • 32 Porta F, Mussa A, Concolino D, Spada M, Ponzone A. Dopamine agonists in 6-pyruvoyl tetrahydropterin synthase deficiency. Neurology 2009; 73 (8) 633-637
    CrossrefPubMedGoogle Scholar
  • 33 Liu KM, Liu TT, Lee NC, Cheng LY, Hsiao KJ, Niu DM. Long-term follow-up of Taiwanese Chinese patients treated early for 6-pyruvoyl-tetrahydropterin synthase deficiency. Arch Neurol 2008; 65 (3) 387-392
    PubMedGoogle Scholar
  • 34 Dudesek A, Röschinger W, Muntau AC , et al. Molecular analysis and long-term follow-up of patients with different forms of 6-pyruvoyl-tetrahydropterin synthase deficiency. Eur J Pediatr 2001; 160 (5) 267-276
    CrossrefPubMedGoogle Scholar
  • 35 Echenne B, Roubertie A, Assmann B , et al. Sepiapterin reductase deficiency: clinical presentation and evaluation of long-term therapy. Pediatr Neurol 2006; 35 (5) 308-313
    CrossrefPubMedGoogle Scholar